Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0VFBIW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AMG-224
|
|||||
| Synonyms |
AMG 224; AMG-224; AMG22 4; AMG224
Click to Show/Hide
|
|||||
| Organization |
Amgen, Inc.
|
|||||
| Drug Status |
Phase 1 (Terminated)
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
Undisclosed
|
|||||
| Antibody Name |
Anti-human BCMA IgG1 Anti-ody
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Puchem SID | ||||||
| ChEBI ID | ||||||
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
23.00% (heavily pretreated population of patients with R/R MM with a median of seven lines of prior therapy)
60.00% (in a phase 1 trial of GSK2857916) |
|||
| Patients Enrolled |
Relapsed or refractory (R/R) multiple myeloma (MM).
|
||||
| Administration Dosage |
Every 3 weeks (Q3W) at prespecified doses of 30-300 mg in a 3+3 design.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02561962 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 first in human study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 224 in subjects with relapsed or refractory multiple myeloma. | ||||
| Primary Endpoint |
AmG 224 was generally well tolerated up to 190 mg Q3W.
|
||||
| Other Endpoint |
ORR=23.00% (95% CI,11.00-39.00%), including six responses in dose escalation and three responses in the dose expansion. Two (5.00%) patients were CR and 7 (18.00%) patients were PR.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT02561962 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 first in human study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 224 in subjects with relapsed or refractory multiple myeloma. | ||||
References